# Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)

> **NCT06314087** · PHASE2 · RECRUITING · sponsor: **The University of Hong Kong-Shenzhen Hospital** · enrollment: 154 (estimated)

## Conditions studied

- Advanced Tumors

## Interventions

- **OTHER:** Placebo + conventional treatment including radiotherapy
- **COMBINATION_PRODUCT:** Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine

## Key facts

- **NCT ID:** NCT06314087
- **Lead sponsor:** The University of Hong Kong-Shenzhen Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-31
- **Primary completion:** 2026-08-16
- **Final completion:** 2026-08-31
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06314087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06314087, "Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06314087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*